Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2017-04-05 Regulatory Filings
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Other Report or Announcement
Regulatory Filings Classification · 95% confidence The document is very short (1886 characters) and explicitly states, "Attached hereto is a report on *The Company unveils expanded HCDR1 preclinical data for the treatment of Sjogren's Syndrome.*" followed by a filename (*XTL_6_K__1_050417_isa.pdf*). This structure indicates that the document itself is an announcement about the publication of another report, rather than the full report content. Since it is a regulatory announcement published via MAGNA (Israel Securities Authority/Tel Aviv Stock Exchange system) and serves to inform the market about the release of specific information (preclinical data), it fits best under the general category for regulatory announcements that don't fit a more specific financial report type. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for an announcement of published material, especially when the document is clearly an announcement wrapper rather than the substantive report itself (Rule 2). Although it relates to scientific/clinical data, none of the specific codes (like ER, IR, AR) fit the wrapper nature of this filing.
2017-04-05 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It contains a press release announcing expanded preclinical data for a drug candidate, hCDR1, for the treatment of Sjögren’s syndrome. The document includes background information about the disease, the drug, and the company, as well as a cautionary statement about forward-looking information. There are no financial statements, detailed financial analysis, or comprehensive management discussion of financial results. The document is primarily a regulatory announcement of new scientific data and business updates rather than a full financial report or earnings release. Form 6-K filings are typically used for current reports by foreign private issuers and often fall under the category of Regulatory Filings (RNS) in this classification scheme. The document length (9449 characters) and content confirm it is not a brief announcement or a full annual/interim report but a regulatory filing with substantive business update information. Therefore, the appropriate classification is Regulatory Filings (RNS).
2017-04-05 English
Immediate Report
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'Form 6-K' and is filed 'Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934' for a 'Report of Foreign Private Issuer'. Form 6-K filings are used to report material information that a foreign private issuer is required to disclose to its home country's securities regulator or stock exchange, or that it makes public in its home country. This type of filing does not map directly to the standard US periodic reports (10-K, 10-Q, 8-K). Among the provided categories, 'Regulatory Filings' (RNS) is the most appropriate fallback for general, non-standardized regulatory announcements from foreign issuers that don't fit specific categories like Director's Dealing (DIRS) or Dividend Notices (DIV). The content announces the CFO's resignation, which is material information, but the document structure is defined by the SEC filing type (6-K), making RNS the best fit as a general regulatory disclosure.
2017-04-05 English
Immediate Report
Board/Management Information Classification · 98% confidence The document is an 'Immediate Report' filed under Israeli regulations (Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000) and reported via MAGNA to the Israel Securities Authority and Tel Aviv Stock Exchange. The core content announces the receipt of a notification from the Chief Financial Officer (Mr. David Kestenbaum) regarding his desire to cease his services. This constitutes an announcement of a change in senior management. Based on the definitions, 'Board/Management Information' (MANG) is the appropriate category for announcements of changes in senior management.
2017-04-05 English
FORM 6-K
Board/Management Information Classification · 95% confidence The document is a Form 6-K filing by XTL Biopharmaceuticals Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily announces the resignation of the company's CFO and includes a forward-looking statement caution. There are no financial statements or detailed financial data presented. The document is a regulatory announcement about management change rather than a full management report or annual/interim report. Given the nature of the announcement about a senior management change, this fits best under Board/Management Information (MANG). The document length is 5668 characters, which is sufficient for a substantive announcement but does not contain financial data or detailed report content. Therefore, the classification is MANG with high confidence.
2017-04-04 English
Report of Periodic or Interim Report
Annual Report Classification · 100% confidence The document is an amendment to an annual report (Form 20-F/A) filed with the SEC. It explicitly identifies itself as an 'Amendment No. 1' to the 'annual report on Form 20-F' for the fiscal year ended December 31, 2016. Since Form 20-F is the standard annual report for foreign private issuers, it falls under the 10-K category in the provided schema. FY 2016
2017-04-03 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.